A Study of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP) — AGNOSTOS

Unknown Primary Tumors Clinical Trial

Official title:
A Phase II, Randomized, Multicenter Study to Assess the Efficacy of Nab-paclitaxel-based Doublet as First Line Therapy in Patients With Cancer of Unknown Primary (CUP): The AGNOSTOS Trial

Status Completed

Clinical Trial Summary

Agnostos Trial is a multicentric phase 2 randomized trial with a 'pick-the-winner design' in chemonaive patients with cancer of unknown primary. It will assess the efficacy of the two best active single agent - carboplatin or gemcitabine - added to an innovative taxane back bone (nab-Paclitaxel). Agnostos trial is a part of a larger clinical and translational initiative to improve the outlook of patients with cancer of unknown primary through evaluation of novel chemotherapeutic regimens.

Clinical Trial Description

Treatment-naïve patients with CUP diagnosis confirmed according to CUP Diagnostic Guidelines, will be enrolled into AGNOSTOS trial. Patients will be randomized upfront to receive a nab-paclitaxel-based duplet adding either carboplatin or gemcitabine until progression or unacceptable toxicity (randomization 1:1, n= 120; 60 per arm). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02607202
Study type	Interventional
Source	Fondazione del Piemonte per l'Oncologia
Contact
Status	Completed
Phase	Phase 2
Start date	March 2015
Completion date	January 31, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04028479` - The Registry of Oncology Outcomes Associated With Testing and Treatment
Withdrawn	`NCT00458315` - Cisplatin/Paclitaxel/Gemcitabine +/- Avastin in Patients With Unknown Primary Tumor	Phase 2
Withdrawn	`NCT04276597` - Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.	Phase 2
Active, not recruiting	`NCT00201734` - Capecitabine, Carboplatin and Weekly Paclitaxel for Patients With Solid Tumors and Adenocarcinoma of Unknown Primary	Phase 1/Phase 2
Recruiting	`NCT04273061` - Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity	Phase 2
Recruiting	`NCT06140992` - PaCIFiC-CUP Classifies Cancer of Unknown Primary
Recruiting	`NCT05046444` - Solving Riddles Through Sequencing
Recruiting	`NCT06100081` - Real-time Targeted Fluorescence Endoscopy for Detection of the Primary Cancer Lesion in Patients With a Metastasis of Unknown Primary Tumor in the Head and Neck	N/A
Completed	`NCT03418480` - HARE-40: HPV Anti-CD40 RNA vaccinE	Phase 1/Phase 2
Available	`NCT04100694` - Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor